Does the histopathological subtype of primary basal cell carcinoma predict the subtype of secondary tumours? What role do genetic mutations play?

Background: Basal cell carcinoma (BCC) is one of the most common malignancies in the world. The frequency of histopathological subtypes and the distribution on the body of BCC has been well documented. Less has been written on the nature of secondary tumours. The genetics of BCC is starting to be understood, particularly with the advent of newer medical treatments (hedgehog inhibitors). Objectives: To determine if primary basal cell carcinoma histopathological subtype predicts secondary tumour subtype, as well as their anatomical distribution. Methods: A retrospective case series of patients over the age of 18 was performed from 2009 to 2014, with at least two separate diagnoses of BCC. Results: In 394 identified patients, a total of 1355 BCCs arose in the cohort over the 6-year study period. The number of secondary BCCs per patient ranged from 2 to 19 tumours. Nodular BCC was the most likely to reoccur in secondary tumours (53.3%), followed by mixed subtypes (45.7%). Conclusions: Within our study, we did find a predisposition for secondary BCCs to be of the same histopathological subtype as the primary, particularly with respect to nodular and mixed tumours. Furthermore, we found that secondary tumours were also more likely to occur on the same anatomical site as the primary tumour. We are only just beginning to under the genetic mutations involved in subtype formation.

The versatility of the temporoparietal fascial graft (TPFG) in orbital implant exposure.

BACKGROUND: The use of TPFGs for hydroxyapatite, porous polyethylene and silicone implant exposure has been described previously. To the authors' knowledge, this is the first description of this technique for acrylic implant exposure and paediatric patients. PURPOSE: To demonstrate the versatility of the TPFG in orbital implant exposures of varying duration, implant types and patient age as well as for recurrent exposure. METHODS: Retrospective, interventional, non-comparative case series. RESULTS: Twelve patients (13 grafts) are presented with a mean follow-up of 9.5 months. The duration of exposure prior to grafting ranged from 1-11 months occurring in bioceramic, hydroxyapatite, porous polyethylene and acrylic implant types. There were 2 graft failures (success rate 84.6%), one of which was treated with a 2nd TPFG. Two of the cases were from the paediatric age group. CONCLUSION: This study provides further supporting evidence for the safety and efficacy of the TPFG and demonstrates the use of this graft in a variety of different clinical situations.

Bilateral optic disc oedema and associated optic neuropathy in the setting of FOLFOX chemotherapy.

BACKGROUND: To report a case of bilateral optic disc oedema and associated optic neuropathy in the setting of FOLFOX chemotherapy. CASE PRESENTATION: A case of a 57-year-old male being treated with FOLFOX chemotherapy for stage 3B colorectal cancer, who developed bilateral optic disc oedema and associated left sided optic neuropathy is described. The patient presented following cycles 7, 8 and 9 of chemotherapy with a history of bilateral simultaneous intermittent inferior altitudinal field defects. These episodes progressed to bilateral optic nerve oedema and a subsequent left sided optic neuropathy. The patient's symptoms and oedema regressed with discontinuation of chemotherapy. CONCLUSION: This is the first report suggesting a vasospastic role of 5-fluoruracil in 5-FU associated optic neuropathy. It highlights that 5-FU may have the potential to cause arterial vasospasm outside the cardiac vasculature, resulting in end-organ optic nerve ischaemia.